OQROGet OQRO Pro
Insider trade

Newamsterdam Pharma Co N.V. (NAMS)Director sold ~$1.06M

Johannes Jacob Pieter Kastelein, Director at Newamsterdam Pharma Co N.V., sold ~$1.06M of Newamsterdam Pharma Co N.V. shares.

~$1.06M
Approx. value · 42K sh @ $25.08
77K
Holds after · shares reported
Traded
Aug 22, 2025
Filed
Aug 25, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jun 24, 2025InsiderDirector purchased ~$46K of NAMS shares in the open market
  2. Jun 25, 2025InsiderDirector purchased ~$23K of NAMS shares in the open market
  3. Jul 15, 2025Insider · 1 personInsiders: 2 sales (~$1.0M)
  4. Jul 16, 2025InsiderOfficer sold ~$1.08M of NAMS shares in the open market
  5. Aug 11, 2025InsiderDirector purchased ~$11K of NAMS shares in the open market
  6. Aug 21, 2025InsiderDirector sold ~$1.21M of NAMS shares in the open market
  7. Aug 22, 2025 · this disclosureInsiderDirector sold ~$1.06M of NAMS shares in the open market

What came next

  1. Aug 22, 2025InsiderDirector sold ~$195K of NAMS shares in the open market
  2. Aug 25, 2025InsiderOfficer sold ~$206K of NAMS shares in the open market
  3. Sep 3, 2025InsiderOfficer sold ~$453K of NAMS shares in the open market
  4. Sep 8, 2025InsiderDirector purchased ~$31K of NAMS shares in the open market
  5. Sep 9, 2025Insider · 1 personInsiders: 2 sales (~$3.9M)
  6. Sep 15, 2025InsiderDirector purchased ~$16K of NAMS shares in the open market
  7. Nov 5, 2025Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Newamsterdam Pharma Co N.V.

For Newamsterdam Pharma Co N.V., OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 6 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its NAMS page.

Other recent filings by Johannes Jacob Pieter Kastelein, Chief Scientific Officer

The full history of Johannes Jacob Pieter Kastelein, Chief Scientific Officer is on the profile page.

How this filing works

Other disclosures at Newamsterdam Pharma Co N.V.

Everything OQRO holds on this company is on its NAMS page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data